In 88 people aged ≥12 with sickle cell disease and leg ulcers, 12 weeks of voxelotor did not improve complete ulcer resolution vs placebo (6.7% vs 7.0%; p>0.99). Sickle cell crises were more common on voxelotor (44.4% vs 25.6%); 11 participants died.
RCTn = 88
Ogutu et al. Phase 3, randomised, placebo-controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE